Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites
Overview
Authors
Affiliations
Purpose: The purpose of this study is to characterize the mutational landscape across the spectrum of urothelial carcinoma (UC) to identify mutational features and potential therapeutic targets.
Experimental Design: Using targeted exome sequencing ( = 237 genes), we analyzed the mutation spectra of 82 low-grade nonmuscle-invasive bladder cancers (LG-NMIBC), 126 high-grade (HG) NMIBC, 199 muscle-invasive bladder cancers (MIBC), 10 LG-upper tract urothelial cancers (LG-UTUC), and 55 HG-UTUC.
Results: and mutations were significantly more common in LG-NMIBC (72% and 44%, respectively) versus other bladder subtypes. alterations were also enriched in LG-UTUC versus HG-UTUC tumors (80% vs. 16%). In contrast, and mutations were significantly more frequent in all 3 HG urothelial carcinoma subtypes than in LG-NIMBC (45%-58% vs. 4%; 9%-22% vs. 0; respectively). Among LG-NMIBC tumors, mutations were more common in women than in men (71% vs. 38%). HG-NMIBC and MIBC had higher tumor mutational burden (TMB) than LG-NMIBC ( = 0.001 and < 0.01, respectively). DNA-damage repair (DDR) alterations were associated with a higher TMB in HG-NMIBC and MIBC tumors, and these two tumor types were also enriched for an APOBEC mutational signature compared with LG-NMIBC and HG-UTUC. Alterations in , and correlated with worse overall survival in HG-UTUC and occurred concurrently.
Conclusions: Our analysis suggests that a fraction of MIBCs likely arise from precursor lesions other than LG-NMIBC. mutations are twice as common in women with LG-NIMBC than those in men. DDR gene mutations and APOBEC mutagenesis drive mutations in HG-NMIBC and MIBC. UTUC has a distinct mutation profile from bladder cancer.
Natural history of bladder cancer: Validation of the multiple pathway model in multi-omics era.
Bedore S, Aguilar K, Lokeshwar V Urol Oncol. 2025; 43(2):88-93.
PMID: 39986827 PMC: 11850028. DOI: 10.1016/j.urolonc.2024.10.003.
Jin K, Ding Y, Xu J, Liu Z, Zeng H, Su X J Immunother Cancer. 2025; 13(1.
PMID: 39762080 PMC: 11749520. DOI: 10.1136/jitc-2024-010964.
Lemberger U, Ernhofer B, Krieger S, Bruchbacher A, Oszwald A, Laukhtina E Eur Urol Open Sci. 2024; 71:38-48.
PMID: 39717660 PMC: 11664179. DOI: 10.1016/j.euros.2024.10.022.
Predicting response to bacillus Calmette-Guerin in high-risk non-muscle invasive bladder cancer.
Soltani-Tehrani A, Kumar A, Pohar K Transl Cancer Res. 2024; 13(11):6489-6502.
PMID: 39697728 PMC: 11651738. DOI: 10.21037/tcr-24-180.
The Evolving Molecular Landscape and Actionable Alterations in Urologic Cancers.
Antar R, Fawaz C, Gonzalez D, Xu V, Drouaud A, Krastein J Curr Oncol. 2024; 31(11):6909-6937.
PMID: 39590142 PMC: 11593205. DOI: 10.3390/curroncol31110511.